Hillstream BioPharma, Inc. (HILS) — Financial statements
Income statement, balance sheet, and cash flow for Hillstream BioPharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓51.9% | 6↑79.6% | 4↑56.2% | 2↑23.6% | 2 | |
| General & Administrative Expenses | 17↑181.9% | 6↑2.5% | 6↑28.1% | 5↑237.2% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑181.9% | 6↑2.5% | 6↑28.1% | 5↑237.2% | 1 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 20↑61.7% | 12↑31.5% | 9↑37.4% | 7↑114.5% | 3 | |
| Total Costs & Expenses | 0.00 | 0.00↓100.0% | 9↑37.4% | 7↑114.5% | 3 | |
| Operating Results | ||||||
| Operating Income | -20↓61.7% | -12↓31.5% | -9↓37.4% | -7↓114.5% | -3 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 0.17↓100.0% | 1,569↑85513.8% | 2 | |
| EBITDA | -20↓61.7% | -12↓31.5% | -9↓37.4% | -7↓1605.0% | 0.46 | |
| EBIT | 0.00 | 0.00↑100.0% | -9 | 0.00↑100.0% | -1 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00↓100.0% | 0.17↑110.6% | -2↓91.4% | -0.83 | |
| Interest Income | 0.04↓83.4% | 0.25↑63.7% | 0.15 | 0.00 | 0.00 | |
| Interest Expense | -0.03↓107.1% | -0.01↑17.1% | -0.02↓101.0% | 2↑91.4% | 0.83 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -0.12 | 0.00↑100.0% | -2 | |
| Other Income / Expenses | -22↓9412.1% | 0.24↑73.5% | 0.14↑108.6% | -2↓258.9% | 1 | |
| Income Before Tax | -42↓245.2% | -12↓30.9% | -9↓10.0% | -8↓284.0% | -2 | |
| Income Tax Expense | -6 | 0.00 | 0.00 | 0.00↓100.0% | 0.83 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -36 | 0.00↑100.0% | -9↓10.0% | -8↓178.9% | -3 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -36↓194.5% | -12↓30.9% | -9↓10.0% | -8↓178.9% | -3 | |
| Bottom-Line Net Income | -36↓194.5% | -12↓30.9% | -9↓10.0% | -8↓178.9% | -3 | |
| EPS (Basic) | -1.12↑88.1% | -9.41↓31.8% | -7.14↓852.0% | -0.75↓150.0% | -0.30 | |
| EPS (Diluted) | -1.12↑88.1% | -9.41↓31.8% | -7.14↓852.0% | -0.75↓150.0% | -0.30 | |
| Weighted Average Shares | 32↑2372.4% | 1↓0.7% | 1↓88.4% | 11↑9.1% | 10 | |
| Weighted Average Diluted Shares | 32↑2372.4% | 1↓0.7% | 1↓88.4% | 11↑9.1% | 10 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.